Dyne hires Bibbiani as SVP, head of development

Muscle disease company Dyne Therapeutics Inc. (NASDAQ:DYN) hired Francesco Bibbiani as SVP, head of development. Bibbiani was VP of global clinical development at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), where he oversaw development of neuromuscular and neurology programs. 

O'Melveny & Myers said Gregory Morris joined the firm’s New York office as a partner in its IP and technology practice. Morris has represented pharma companies in Hatch-Waxman and biosimilars cases, as well as in inter partes review proceedings before the U.S. Patent and Trademark Office...